Guides for diagnostic development

How to validate a qPCR or ddPCR assay under CLIA

For a lab-developed or modified PCR test, CLIA requires the lab to establish accuracy, precision, analytical sensitivity, analytical specificity including interferences, reportable range, reference intervals and any other characteristic the test needs, before reporting patient results. An unmodified FDA-cleared kit needs only a shorter verification.

Before you start

Write the plan first

Get the laboratory director to sign a validation plan that fixes:

  • Intended use: target, specimen types, qualitative or quantitative result, and the clinical decision it supports.
  • The complete workflow: extraction, input volume, instrument, master mix, primers and probes, controls, software and thresholds. Changing any of these later may mean revalidating.
  • Acceptance criteria for every study, set before any data are collected.
  • Specimens: real patient specimens wherever possible, plus contrived samples for rare targets and low concentrations.
Follow MIQE for qPCR and digital MIQE (dMIQE) for ddPCR when documenting assay design and analysis.

The studies

What to establish, and a common design

Accuracy

40 or more specimens across the range compared with a reference method, an orthogonal assay or characterized samples. Report positive and negative agreement, or bias and regression.

CLSI EP09, EP12

Precision

2–3 levels including one near the cutoff, in replicate across several days, operators, reagent lots and instruments.

CLSI EP05, EP12

Analytical sensitivity

Dilution series around the expected limit, about 20 replicates per level. The limit of detection is the lowest level detected in at least 95% of replicates; quantitative tests also set a limit of quantitation.

CLSI EP17

Analytical specificity

Related organisms or sequences (homologs, pseudogenes), plus interferents such as hemoglobin, lipids, heparin and extraction carryover.

CLSI EP07

Reportable range

For quantitative tests, 5 or more levels across the range; for qPCR, a standard curve with efficiency of about 90–110%.

CLSI EP06

Reference interval and more

For most qualitative molecular tests the normal result is "not detected"; document the rationale. Also cover specimen and extract stability, extraction recovery, carryover and control performance.

CLSI EP28

Sample numbers are common starting points, not regulatory minimums; the laboratory director sets the final acceptance criteria.

CAP accreditation

What CAP adds to CLIA

If your laboratory is CAP-accredited, the All Common checklist adds specific validation requirements.

Director approval

A written evaluation of the validation, signed by the laboratory director or qualified designee, before any patient testing.

COM.40000

Accuracy samples

At least 20 samples for an LDT or modified test, across the range; for qualitative tests, positives, negatives and low positives. Fewer needs a documented director justification; QC material does not count.

COM.40350, COM.40300

Precision, sensitivity, specificity

Within-run and between-run precision; the detection limit; analytical specificity; documented interferences with a plan of action; reportable range.

COM.40310–40600

QC and calibration

Written QC and calibration procedures based on the validation data.

COM.40610

Clinical claims

Any sensitivity, specificity or risk claim validated with at least 20 positive and negative samples, unless peer-reviewed literature supports it.

COM.40640

Records and re-verification

Keep a list of LDTs and modified tests; state on reports that the lab developed the test; verify each identical instrument; re-verify within 30 days after a break in testing.

COM.40200, COM.40630, COM.40100

Item numbers are from the August 2017 CAP All Common checklist excerpt; check your current edition. Molecular tests also fall under CAP's Molecular Pathology checklist.

qPCR vs ddPCR

Where the validations differ

qPCR

  • Quantifies against a standard curve (Cq values).
  • Validate curve efficiency, slope, linearity and the stability of the standards.
  • Limit of detection set by Cq cutoff and replicate detection rate.
  • Main precision risk: pipetting of standards and run-to-run curve drift.
  • Strength: wide dynamic range and high throughput.

ddPCR

  • Absolute copies, by counting positive partitions; no standard curve.
  • Validate partition volume, minimum accepted droplet count and the positive/negative threshold.
  • Set the limit of blank from false-positive droplets in negative samples first.
  • Main precision risk: partition count and threshold placement for rare variants.
  • Strength: rare variants and small fold-changes, such as liquid biopsy mutations.

After validation

Keep it validated

The laboratory director signs a validation report before the first patient result. After that, CLIA expects quality control with every run, proficiency testing (or an alternative assessment) at least twice a year, and revalidation when the workflow changes. To test New York patients, the state's Clinical Laboratory Evaluation Program must approve the test first. Data collected to FDA expectations can later support a 510(k) or De Novo submission.

Source: 42 CFR 493.1253, Establishment and verification of performance specifications

Need a qPCR or ddPCR assay validated?

We design validation plans, run the studies and operate the test in our CLIA/CAP laboratory.